Mycobacterial susceptibility testing and reporting: When, how, and what to test

Clinical Microbiology Newsletter

Volumn 27, Issue 9, 2005, Pages 67-72

  Woods, Gail L ^a  

^a ARUP LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOSALICYLIC ACID; AZITHROMYCIN; CAPREOMYCIN; CEFOXITIN; CLARITHROMYCIN; CYCLOSERINE; DOXYCYCLINE; ETHAMBUTOL; ETHIONAMIDE; IMIPENEM; ISONIAZID; KANAMYCIN; LINEZOLID; OFLOXACIN; PYRAZINAMIDE; RIFABUTIN; RIFAMPICIN; STREPTOMYCIN; SULFAMETHOXAZOLE; TOBRAMYCIN;

ACTINOBACTERIA; DRUG SENSITIVITY; MINIMUM INHIBITORY CONCENTRATION; MYCOBACTERIUM; MYCOBACTERIUM AVIUM; MYCOBACTERIUM KANSASII; MYCOBACTERIUM MARINUM; MYCOBACTERIUM TUBERCULOSIS; NOCARDIA; NONHUMAN; REVIEW; TUBERCULOSIS;

EID: 20144368813     PISSN: 01964399     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0196-4399(05)80022-4     Document Type: Article

References (22)

1. National Committee for Clinical Laboratory Standards Susceptibility testing of Mycobacteria, Nocardia, and other Aerobic Actinomycetes. Approved Standard M24-A 2003 National Committee for Clinical Laboratory Standards
2. Kent P.T., and G.P. Kubica Antituberculosis chemotherapy and drug susceptibility testing P.T. Kent G.P. Kubica Public health mycobacteriology: a guide for the level III laboratory 1985 Centers for Disease Control and Prevention Wayne, PA 159 184
3. Tenover F.C. The resurgence of tuberculosis: is your laboratory ready? J. Clin. Microbiol. 31 1993 767 770
4. Siddiqi S.H., J.E. Hawkins, and A. Laszlo Interlaboratory drug susceptibility testing of Mycobacterium tuberculosis by a radiometric procedure and two conventional methods J. Clin. Microbiol. 22 1985 919 923
5. Scarparo C. Evaluation of the fully automated BACTEC MGIT 960 for testing susceptibility of Mycobacterium tuberculosis to pyrazinamide, streptomycin,isoniazid, rifampin, and ethambutol and comparison with the radiometric BACTEC 460TB method J. Clin. Microbiol. 42 2004 1109 1114
6. Bergmann J.S., and G.L. Woods Evaluation of the ESP culture system II for testing susceptibilities of Mycobacterium tuberculosis isolates to four primary antituberculousdrugs J. Clin. Microbiol. 36 1998 2940 2943
7. Bergmann J.S., G. Fish, and G.L. Woods Evaluation of the BBL MGIT (Mycobacterial Growth Indicator Tube) AST SIRE system for antimycobacterial susceptibility testing of Mycobacteriumtuberculosis to 4 primary antituberculous drugs Arch. Pathol. Lab. Med. 124 2000 82 86
8. Wallace R.J. Jr. Diagnosis and treatment of disease caused by nontuberculous mycobacteria. American Thoracic Society statement Am. J. Resp. Crit. Care Med. 156 1997 S1 S25
9. Inderlied C.B. Microbiology and minimum inhibitory concentration testing for Mycobacterium avium complex prophylaxis Am. J. Med. 102 1997 2 10
10. Chaisson R.E. Clarithromycin therapy for bacteremic Mycobacterium avium complex disease. A randomized, double-blind, dose-ranging study in patients with AIDS. AIDS Clinical Trials Group Protocol 157 Study Team Ann. Intern. Med. 121 1994 905 911
11. Sison J.P. Treatment of Mycobacterium avium complex infection: Do the results of in vitro susceptibility tests predict therapeutic outcome in humans? J. Infect. Dis. 173 1996 677 683
12. Shafran S.D. Does in vitro susceptibility to rifabutin and ethambutol predict the response to treatment of Mycobacterium avium complex bacteremia withrifabutin, ethambutol, and clarithromycin? Clin. Infect. Dis. 27 1998 1401 1405
13. Siddiqi S.H. Rapid broth macrodilution method for determination of MICs for Mycobacterium avium isolates J. Clin. Microbiol. 31 1993 2332 2338
14. Brown B.A., R.J. Wallace Jr., and G.O. Onyi Activities of clarithromycin against eight slowly growing species of nontuberculous mycobacteria, determined by using a broth microdilution MICsystem Antimicrob. Agents Chemother. 36 1992 1987 1990
15. Heifets L. Susceptibility testing of Mycobacterium avium complex isolates Antimicrob. Agents Chemother. 40 1996 1759 1767
16. Woods G.L. Multisite reproducibility of results obtained by two broth dilution methods for susceptibility testing of Mycobacterium avium complex J. Clin. Microbiol. 41 2003 627 631
17. Wallace R.J. Jr. Rifampin-resistant Mycobacterium kansasii Clin. Infect. Dis. 18 1994 736 743
18. Steadham J.E., S.K. Stall, and J.L. Simmank Use of the Bactec system for drug susceptibility testing of Mycobacterium tuberculosis, M. kansasii, and M. avium complex Diagn. Microbiol. Infect. Dis. 3 1985 33 40
19. Wallace R.J. Jr. Susceptibility testing of slowly growing mycobacteria by a microdilution MIC method with 7H9 broth J. Clin. Microbiol. 24 1986 976 981
20. Swenson J.M. Antimicrobial susceptibility of five subgroups of Mycobacterium fortuitum and Mycobacterium chelonae Antimicrob. Agents Chemother. 28 1985 807 811
21. Wallace R.J. Jr., B.A. Brown, and G.O. Onyi Susceptibilities of Mycobacterium fortuitum biovar fortuitum and the two subgroups of Mycobacterium chelonae to imipenem, cefmetazole, cefoxitin, and amoxicillin-clavulanic acid Antimicrob. Agents Chemother. 35 1991 773 775
22. Woods G.L. Multisite reproducibility of results obtained by the broth microdilution method for susceptibility testing of Mycobacterium abscessus,Mycobacterium chelonae, and Mycobacterium fortuitum J. Clin. Microbiol. 37 1999 1676 1682